PD 0200390 dose ranging trial: A randomized, double blind, parallel group, placebo controlled, multicenter outpatient trial of PD 0200390 in adults with primary insomnia.
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2012
At a glance
- Drugs Atagabalin (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Pfizer
- 24 Jul 2012 Actual end date changed from Dec 2008 to Jan 2009 as reported by ClinicalTrials.gov.
- 29 Jan 2009 Actual patient numbers (682) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.